Kevin Pang, PharmD

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Systemic treatment options have historically been limited to traditional chemotherapy agents.

Significant advancements have changed the treatment landscape and clinical practice procedures.

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.